Relevant bibliographies by topics / Bronchodilator

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Bronchodilator'

Author: Grafiati
Published: 4 June 2021
Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bronchodilator.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bronchodilator"

1

Levine, Hagit, Ophir Bar-On, Vered Nir, Nicole West, Yotam Dizitzer, Huda Mussaffi, and Dario Prais. "Reversible Bronchial Obstruction in Primary Ciliary Dyskinesia." Journal of Clinical Medicine 11, no. 22 (November 16, 2022): 6791. http://dx.doi.org/10.3390/jcm11226791.

Full text
Abstract:
Background: Inhaled bronchodilators are frequently used among patients with primary ciliary dyskinesia (PCD), although neither the effectiveness nor the prevalence of their use is known, due to the paucity of relevant studies. Methods: This is a retrospective analysis of pre- and post-bronchodilator spirometry results, of patients with PCD from two centers. Correlations were examined of bronchodilator response, with asthma and atopy markers. Results: Of 115 patients, 46 (40%) completed spirometry pre- and post-bronchodilation. Of these, 26 (56.5%) demonstrated reversible airway obstruction (increase in %FEV1 predicted ≥ 10%). Obstruction reversibility was not found to be associated with a family history of asthma, blood eosinophil level, elevated IgE, or atopy symptoms. Of the 46 patients who completed bronchodilator spirometry, 29 (63%) were regularly using bronchodilators and inhaled corticosteroids. Conclusions: More than half of patients with PCD presented with reversible airway obstruction, without any correlation to markers of personal or familial atopy. Inhaled bronchodilators and corticosteroid therapies are commonly used for treating PCD. Evaluating bronchodilator response should be considered, and its effectiveness should be further studied.
APA, Harvard, Vancouver, ISO, and other styles
2

Lloberes, P., L. Ramis, JM Montserrat, J. Serra, J. Campistol, C. Picado, and A. Agusti-Vidal. "Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease." European Respiratory Journal 1, no. 6 (June 1, 1988): 536–39. http://dx.doi.org/10.1183/09031936.93.01060536.

Full text
Abstract:
This study evaluates the effect of three different bronchodilators (beta 2-adrenergic, anticholinergic and methylxanthine) alone and in randomized sequence, during an exacerbation in thirteen patients with chronic obstructive pulmonary disease. Dose-response curves were obtained for inhaled salbutamol and inhaled ipratropium bromide. The bronchodilator effect of a perfusion of aminophylline was also assessed. When a plateau of bronchodilatation was achieved with one agent, one dose of a second bronchodilator was administered to see whether additional bronchodilation could be achieved. The increments in FEV1 and FVC were similar with the three agents. The addition of a second bronchodilator did not result in significant increments in most of the patients. In at least half of the patients the doses of salbutamol and ipratropium that produced the maximal bronchodilatation were twice that currently employed.
APA, Harvard, Vancouver, ISO, and other styles
3

Cazzola, Mario, Clive Page, and Maria Gabriella Matera. "Ensifentrine: A First-in-class Bifunctional Drug for the Treatment of Chronic Obstructive Pulmonary Disease." US Respiratory & Pulmonary Diseases 7, no. 2 (2022): 48. http://dx.doi.org/10.17925/usrpd.2022.7.2.48.

Full text
Abstract:
Ensifentrine is an inhaled ‘bifunctional’ dual phosphodiesterase 3/4 inhibitor that exhibits both bronchodilator and anti-inflammatory activities. Preclinical research has shown that ensifentrine can induce significant relaxation of human bronchi in vitro and suggested the possibility of a synergistic interaction between ensifentrine and β2-adrenoceptor agonists and, mainly, muscarinic receptor antagonists. Ensifentrine is the only dual phosphodiesterase 3/4 inhibitor under clinical development for the treatment of chronic obstructive pulmonary disease (COPD). It has been shown to induce bronchodilation, with a peak bronchodilator effect in patients with COPD similar to that seen after salbutamol administration, and anti-inflammatory activity in healthy individuals. Combined with standard bronchodilators (salbutamol, ipratropium or tiotropium), ensifentrine causes additional bronchodilation and, importantly, a significant reduction in hyperinflation in patients with stable moderate to severe COPD. A recent statement on the top-line phase III ENHANCE-2 study reported that ensifentrine induced significant bronchodilation and reduced the risk of moderate-to-severe COPD exacerbations in study participants. Ensifentrine continues to show promise as a novel drug for treating patients with COPD. Nevertheless, it is necessary to understand whether ensifentrine will be able to replace or reduce the use of currently available classes of bronchodilators, and/or whether it will be a valuable add-on therapy to the current standard of care to further optimize bronchodilation. Furthermore, it will be critical to clarify the anti-inflammatory profile of ensifentrine.
APA, Harvard, Vancouver, ISO, and other styles
4

Kopel, Lianne S., Elizabeth S. Klings, Michael C. Monuteaux, Jonathan M. Gaffin, Matthew M. Heeney, and Wanda Phipatanakul. "Bronchodilator Use for Acute Chest Syndrome Among Large Pediatric Hospitals in North America." Clinical Pediatrics 57, no. 14 (September 3, 2018): 1630–37. http://dx.doi.org/10.1177/0009922818796661.

Full text
Abstract:
The utility of bronchodilators to treat acute chest syndrome (ACS) in patients with sickle cell disease is unknown. Our objectives were to examine the variability in bronchodilator use for ACS among pediatric hospitals contributing to a large database and to examine the relationship between bronchodilator use and length of stay (LOS) and mortality. Between 2005 and 2011, bronchodilators were used during 6812/11 328 hospitalizations (60.1%) and use varied from 0.0% to 97.0% (median = 46.0%, interquartile range = 37.0% to 74.0%). Median LOS was 4 days, and interquartile range was 2 to 6 days. Bronchodilator use was associated with a 13.2% increase in LOS (95% confidence interval = 9.2% to 17.3%, P < .001). However, in the subgroup with asthma, bronchodilator use was associated with a 17.9% decrease in LOS (95% confidence interval = 1.7% to 31.4%, P = .03). There is wide variability in bronchodilator use for ACS, and it has variable association with LOS, depending on comorbid asthma. Prospective trials are needed to evaluate bronchodilators for ACS.
APA, Harvard, Vancouver, ISO, and other styles
5

Clifford, Rachel L., and Alan J. Knox. "Future bronchodilator therapy: a bitter pill to swallow?" American Journal of Physiology-Lung Cellular and Molecular Physiology 303, no. 11 (December 1, 2012): L953—L955. http://dx.doi.org/10.1152/ajplung.00303.2012.

Full text
Abstract:
Maintenance of airway tone, prevention of airway obstruction, and acute relief from bronchospasm are key targets of asthma therapy. This role is currently performed by β-agonists. However, chronic use of β-agonists to treat asthma is associated with desensitization of β-agonist signaling and a resultant loss of bronchodilator effect, worsening of airway hyperreactivity, and increased incidence of asthma-related morbidity and mortality. There have been several attempts to identify novel non-β-agonist bronchodilators including ATP-sensitive potassium channel (KATP) agonists such as cromakalim and its active enantiomer BRL-38227 and the cGMP activators atrial natriuretic peptide (ANP) and BAY 41-22722. However, these either have not made it to clinical trial, required high doses, had little effect in patients, or had a high incidence of side effects. Recent data suggests that a novel bronchodilator target exists, the bitter taste receptor TAS2R. Two recent studies [An SS, Wang WC, Koziol-White CJ, Ahn K, Lee DY, Kurten RC, Panettieri RA Jr, Liggett SB. Am J Physiol Lung Cell Mol Physiol 303: L304–L311, 2012; Pulkkinen V, Manson ML, Säfholm J, Adner M, Dahlén SE. Am J Physiol Lung Cell Mol Physiol. doi:10.1152/ajplung.00205.2012.] provide new understanding of the signaling pathways utilized by TAS2Rs to mediate their bronchodilatory effects and how TAS2R-mediated bronchodilation is affected by β-agonist signaling desensitization. As our understanding of TAS2Rs and their agonists increases, they move closer to a viable therapeutic option; however, further definition is still required and questions remain to be answered. This editorial focus discusses these studies within the context of existing literature and raises questions and challenges for the future development of bitter (better?) therapies for asthma.
APA, Harvard, Vancouver, ISO, and other styles
6

Rechkina, Olena, Vira Stryzh, and Serhii Rudenko. "LEVEL ASSESSMENT OF CONTROL OF BRONCHIAL ASTHMA IN ADOLESCENTS." JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE, no. 3 2021 (October 29, 2021): 192–98. http://dx.doi.org/10.37621/jnamsu-2021-3-5.

Full text
Abstract:
Introduction. The problem of controlling bronchial asthma in adolescents remains relevant, and its monitoring is more difficult than in other age categories, since during the period of long-term remission the disease can be accompanied by signs of bronchial hyperreactivity to nonspecific irritants, and pulmonary ventilation disorders can have a «latent» character, persisting much longer than the clinical symptoms of the disease, which leads to tactical errors in determining the level of bronchial asthma control and is a risk factor for its progression. Aim: to develop a method for assessing the level of bronchial asthma control in adolescents, when there are no clinical, anamnestic and functional signs of insufficient control of asthma, by using a quality of life questionnaire and an additional bronchodilatory test. Materials and methods. The study included 43 adolescents with mild (41.9 %) and moderate (58.1 %) controlled bronchial asthma. To identify cases of «latent» bronchospasm, a bronchodilatory test with salbutamol was performed and the increase in forced expiratory volume in 1 second (FEV1) was calculated. In the case of an increase in FEV1 ≥ 12.0 %, the presence of «latent» bronchospasm was confirmed. If the increase in FEV1 turned out to be < 12.0 %, a questionnaire was performed using the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) and if the value of the integral indicator of the overall quality of life PAQLQ ≤ 6.5 points, an additional bronchodilator test with a combined bronchodilator (fenoterol / ipratropium bromide). Results. The absence of changes in the initial levels of spirometric parameters was found in all 43 patients (FEV1 > 80.0 %). When carrying out a bronchodilatory test with salbatamol, 7 patients (16.3 %) with a positive response (increase in FEV1 ≥ 12.0 %) were identified, which indicated cases of «latent» bronchospasm and partial control of asthma, and 36 people (83.7 %) with a negative answer (increase in FEV1 < 12.0 %). Among 36 patients with an increase in FEV1 < 12.0 % in the test with salbutamol applied the PAQLQ questionnaire and identified 24 people or 66.7 % with an overall quality of life of ≤ 6.5 points, which reflected the negative impact of adolescents asthma on the quality of life and lack of complete asthma control. This was confirmed in 7 out of 24 people (29.2 %) in an additional bronchodilatory test with a combined bronchodilator, in which they gave a positive response (increase in FEV1 ≥ 12.0 %; r = -0.4, p = 0.02). The reasons for the decrease in the overall quality of life of ≤ 6.5 points in the remaining 17 adolescents were due to psychoemotional states or vegetative-vascular dysfunction, and not to the latent course of «latent» bronchospasm. As a result, among 43 adolescents, 14 patients or 32.6 % with «latent» bronchospasm were found. At the same time, the relative risk of a positive patient response to a bronchodilator test with a combined bronchodilator was 2.1 times higher than during a bronchodilator test with salbutamol (OR = 2.1, 95 % CI 1.1–7.0). Conclusions. Conducting bronchodilatory tests with bronchodilators of various pharmacological groups and questioning patients using the PAQLQ questionnaire on the quality of life makes it possible to establish cases of «latent» bronchospasm even with a negative response to salbutamol, when there are no clinical and anamnestic signs of insufficient asthma control and the FEV1 index exceeds 80.0 % of proper values. Keywords: adolescents, bronchial asthma, control, bronchospasm.
APA, Harvard, Vancouver, ISO, and other styles
7

Adesanoye, Damilola T., and Cynthia J. Willey. "Does Cardiovascular Comorbidity Influence the Prescribing of Bronchodilators in Chronic Obstructive Pulmonary Disease?" Annals of Pharmacotherapy 51, no. 10 (June 2, 2017): 855–61. http://dx.doi.org/10.1177/1060028017712531.

Full text
Abstract:
Background: Cardiovascular disease (CVD) is the most prevalent comorbidity for chronic obstructive pulmonary disease (COPD). Potential adverse cardiovascular events of bronchodilators warrant their cautionary use in the comorbid COPD-CVD population, yet little is known about the prescribing of bronchodilators in this high-risk patient group. Objective: To determine whether comorbid CVD is associated with reduced bronchodilator prescribing in patients with COPD. In addition, we explored how the association was modified by gender, concurrent asthma, and concomitant β-blocker (BB) use. Methods: A cross-sectional study was conducted using the 2010 National Ambulatory Medical Care Survey. All visits among diagnosed COPD patients 40 years and older were examined. Logistic regression on survey-weighted data was used to predict treatment with bronchodilators and determine the influence of gender, asthma, and BBs on bronchodilator prescribing. Results: Among 11 627 061 ambulatory COPD visits, we found a significantly lower bronchodilator treatment rate among patients with comorbid CVD (32.3%) than among patients without CVD (57.6%). The observed effect was modified by gender, asthma, and BBs. Deprescribing was more pronounced for females than males, for nonusers of BBs than users of BBs, and for asthma patients than nonasthma patients. CVD did not affect bronchodilator prescribing in either asthmatic or nonasthmatic males taking BBs. Conclusions: Most COPD patients with concurrent CVD were less likely to be prescribed bronchodilators, with the exception of males who were also prescribed BBs. Thus, this study highlights a specific patient subgroup for whom the guidelines are less likely to be observed.
APA, Harvard, Vancouver, ISO, and other styles
8

Murtisiwi, Lusia. "EVALUATION OF TREATMENT BRONCHODILATORS AND CORTICOSTEROIDS IN COPD INPATIENT IN HOSPITALS DR. MOEWARDI SURAKARTA JANUARY 2016-JUNE 2017." Jurnal Farmasi (Journal of Pharmacy) 1, no. 1 (October 20, 2018): 73–80. http://dx.doi.org/10.37013/jf.v1i1.67.

Full text
Abstract:
Chronic Obstructive Pulmonary Disease (COPD) is one of the cause of mortality and morbidity in worldwide. This study aims to determine the pattern of treatment of bronchodilators with or without corticosteroids and their effects on changes carbon dioxide pressure in blood (PCO2) and oxygen pressure in blood (PO2) in COPD patients of inpatient in RSUD Dr. Moewardi Surakarta January 2016-June 2017. This research is a retrospective descriptive research design, data collecting by tracking medical records patients with 195 samples. The results showed that treatment of COPD patient using single bronchodilator of 30,8%, bronchodilator combination of 57,1%, bronchodilator combination with corticosteroid of 1% and corticosteroid equal to 91,3%.Effect of bronchodilator treatment without corticosteroids on changes in the largest largest PCO2 change of 14.8%, the smallest change in PCO25.9%, the largest PO2 change was 19%, the smallest PO2 change was 5.6%, whereas in patients who received bronchodilator treatment with corticosteroids there was the largest PCO2 change of 87.4%, the smallest PCO2 cha
APA, Harvard, Vancouver, ISO, and other styles
9

Singh, Dave, James F. Donohue, Isabelle H. Boucot, Neil C. Barnes, Chris Compton, and Fernando J. Martinez. "Future concepts in bronchodilation for COPD: dual- versus monotherapy." European Respiratory Review 30, no. 160 (June 1, 2021): 210023. http://dx.doi.org/10.1183/16000617.0023-2021.

Full text
Abstract:
Most patients with COPD are recommended to initiate maintenance therapy with a single long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2-agonist. However, many patients receiving mono-bronchodilation continue to experience high symptom burden, suggesting that patients are frequently not receiving optimal treatment. Treatment goals for COPD are often broad and not individually tailored, making initial treatment response assessments difficult. A personalised approach to initial maintenance therapy, based upon an individual's symptom burden and exacerbation risk, may be more appropriate.An alternative approach would be to maximise bronchodilation early in the disease course of all patients with COPD. Evidence suggests that dual bronchodilation has greater and consistent efficacy for lung function and symptoms than mono-bronchodilation, whilst potentially reducing the risk of exacerbations and disease deterioration, with a similar safety profile to mono-bronchodilators. Improvements in lung function and symptoms between dual- and mono-bronchodilation have also been demonstrated in maintenance-naïve patients, who are most likely to resemble those at first presentation in a clinical setting. Despite promising results, there are several evidence gaps that need to be addressed to allow decision makers to evaluate the merits of a widespread earlier introduction of dual bronchodilation.
APA, Harvard, Vancouver, ISO, and other styles
10

Kamada, Alan. "PHARMACODYNAMIC EFFECTS OF INHALED DRY POWDER FORMULATIONS OF FENOTEROL AND COLFORSIN IN ASTHMA." Pediatrics 94, no. 2 (August 1, 1994): 264–65. http://dx.doi.org/10.1542/peds.94.2.264a.

Full text
Abstract:
Fenoterol administered by inhalation of dry powder caused less tremor and hypokalemia than the MDI formulation, with similar bronchodilator response. Measurable bronchodilation was also observed with colforsin.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Bronchodilator"

1

Witt-Enderby, Paula Ann. "Bronchodilator effects on mechanisms involved in airway responsiveness." Diss., The University of Arizona, 1993. http://hdl.handle.net/10150/186353.

Full text
Abstract:
The traditional approach to treating asthma includes the use of bronchodilator drugs, in particular β₂-adrenergic agonists and anti-cholinergics. It has been shown clinically that regularly scheduled use of both types of bronchodilators may result in a worsening of asthma. This dissertation evaluates the pulmonary effects of long-term bronchodilator administration in our animal model, the rabbit, at the level of the β-adrenergic receptor (βAR) and muscarinic cholinergic receptor (mAChR) located on airway smooth muscle. A four week infusion of the β₂ agonist bronchodilator, albuterol (6 mg/kg/day), resulted in a desensitization (lower affinity) and down-regulation of the βAR in tracheal smooth muscle (predominantly β₂ βAR subtype), mainstem bronchial smooth muscle (predominantly β₂ PAR subtype), and peripheral lung (predominantly β₁ βAR subtype) with no change in either affinity or βAR number in heart (predominantly β₁ βAR) as determined by radioligand binding analysis using the radioligand dihydroalprenolol ([³H] DHA). However, the βAR were not desensitized functionally in that isoproterenol-induced relaxations were not significantly different from control. In contrast, the functional response of the mAChR was increased significantly as compared to control in that the efficacy of methacholine-induced contractions was increased in mainstem bronchial and similarly in tracheal rings. However, the affinity and density of mAChR were not significantly different from the control values as determined by radioligand binding analysis using the radioligand quinuclidinyl benzilate ([³H] QNB). Chronic anti-cholinergic bronchodilator exposure using atropine (4 mg/kg/day) resulted in an increase in the efficacy of methacholine-induced contractile response of mainstem bronchial and tracheal rings with a concomitant increase in mAChR density in both tissues. Differential regulation of the mAChR may be occurring as demonstrated by experiments which show that chronic atropine exposure increased the M₃ mAChR subtype density to a greater extent than the M₂ mAChR subtype. This suggests that the methacholine-induced hyperresponsiveness seen clinically with chronic anti-cholinergic bronchodilator therapy may be due to an up-regulation of the M₃ mAChR in airway smooth muscle involved in bronchoconstriction.
APA, Harvard, Vancouver, ISO, and other styles
2

Jurastow, Innokentij [Verfasser]. "Beta-Nikotinamid-Adenin-Dinukleotid als ein neuer Bronchodilator / Innokentij Jurastow." Gießen : Universitätsbibliothek, 2016. http://d-nb.info/110685313X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Oliver, Clive Lloyd. "Polymorphs, cyclodextrin inclusion complexes and salts of the bronchodilator tulobuterol." Doctoral thesis, University of Cape Town, 2004. http://hdl.handle.net/11427/6356.

Full text
Abstract:
Includes bibliographical references (leaves 199-207).
The aim of this thesis was to prepare polymorphs, cyclodextrin inclusion complexes and salts of tulobuterol, a drug with bronchodilating properties. Polymorphic drugs are of interest to the pharmaceutical industry because of their varied physical properties, whilst the increase in aqueous solubilities of drugs by their inclusion within cyclodextrins or by salt formation is also an important pharmaceutical consideration. Two polymorphs, four cyclodextrin inclusion complexes and three salts of tulobuterol free base were successfully generated in this study.
APA, Harvard, Vancouver, ISO, and other styles
4

Melfi, James. "A descriptive study of beta2-agonist use in asthma patients based on a nationally representative sample /." View online ; access limited to URI, 2005. http://0-wwwlib.umi.com.helin.uri.edu/dissertations/dlnow/3188067.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shelley, Michael Jonathan. "Quality indicators of prescribing and morbidity in asthma : a pharmacoepidemiological study in primary care." Thesis, Keele University, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.388351.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Smith, Emilee. "Lung function in healthy South African adult females." Master's thesis, University of Cape Town, 2015. http://hdl.handle.net/11427/15740.

Full text
Abstract:
Background: Accurate and appropriate spirometry reference values allow for early detection of respiratory illness and perform an important role in monitoring lung health. There is, in general, a scarcity of data from Africa, and the Global Lung Initiative (GLI) has published global reference equations but models did not include data from African studies. The aim of this study was to investigate lung function in a group of healthy South African females and the applicability of the GLI reference equations. Methodology: Maternal lung function testing was undertaken at 6 to 10 weeks post-partum as part of a birth cohort study, the Drakenstein Child Health Study. Pre- and post-bronchodilator spirometry was performed according to a standardised protocol and correlated with clinical information. Bronchodilator response was assessed by repeating spirometry 15 minutes after administration of inhaled 400mcg salbutamol. Results: A total of 462 women were included, mean age 17 years (range 18- 42 years). The GLI reference equations fitted the observed lung function results well for the group of mothers who did not self-report smoking or asthma. There were 64 (14%) mothers with an abnormal Forced Expiratory Volume in 1 Second (FEV 1) result, 60 (13%) mothers with an abnormal Forced Vital Capacity (FVC), and 35 (8%) mothers with an abnormal FEV 1 /FVC ratio. There were 22 (5%) mothers who had reversible FEV 1; the rate of undiagnosed reversibility was 4% of the cohort. High body mass index was associated with a higher risk for poor FVC and FEV 1 /FVC lung function, OR 1.40 (CI: 1.01, 1.65) and OR 1.25 (CI 1.10, 1.95) respectively. Mothers with a higher socio-economic status had better FEV 1 with the adjusted SES OR 0.65 (CI 0.36, 1.08). Conclusions: There was a high prevalence of abnormal lung function in this cohort of South African adult females and a number of cases of undiagnosed reversibility. Spirometry testing is important to diagnose lung disease in South African communities. The GLI's reference equations were appropriate and applicable for a cohort of South African adult women.
APA, Harvard, Vancouver, ISO, and other styles
7

Benayoun, Serge. "The impact of combined inhaled bronchodilator therapy in the treatment of COPD." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape8/PQDD_0028/MQ50720.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Benayoun, Serge. "The impact of combined inhaled bronchodilator therapy in the treatment of COPD /." Thesis, McGill University, 1998. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=21513.

Full text
Abstract:
The introduction of a single inhaler comprising a beta2-agonist and ipratropiurn (CombiventRTM) in the treatment of Chronic Obstructive Pulmonary Disease (COPD) should enhance compliance, improve patient outcomes and result in lower medication costs.
Using the Saskatchewan Health databases, a cohort of subjects initiating treatment with CombiventRTM was identified and followed up to one year. A reference cohort was formed from all subjects who were dispensed, for the first time, two canisters, one of ipratropium and one of inhaled beta 2-agonist, on the same day.
CombiventRTM users presented lower costs associated with inhaled bronchodilators (RR = 0.83; 95% Cl: 0.76 -- 0.92), despite a slight increase in overall use of these medications (RR = 1.16; 95% Cl: 1.07 -- 1.26). Moreover, the use of other respiratory drugs and antibiotics was unchanged (RR = 1.03; 95% Cl: 0.93 -- 1.16).
The availability of a simpler dosing regimen did not alter significantly the treatment of COPD and resulted in appreciable cost savings.
APA, Harvard, Vancouver, ISO, and other styles
9

Hijiya, Kyoko. "BRONCHODILATOR INHALATION DURING EVLP IMPROVES POST-TRANSPLANT GRAFT FUNCTION FOLLOWING WARM ISCHEMIA." Kyoto University, 2017. http://hdl.handle.net/2433/218008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Falls, Richard Drew. "SUBJECTIVE AND OBJECTIVE RESPONSES TO VARIED DOSES OF AN INHALED BRONCHODILATOR (ALBUTEROL)." Thesis, The University of Arizona, 1985. http://hdl.handle.net/10150/275382.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Bronchodilator"

1

Barbara, Juknialis, ed. Inhaled aerosol bronchodilators. Baltimore: Williams & Wilkins, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

L, Rau Joseph, ed. Rau's respiratory care pharmacology. 8th ed. St. Louis, Mo: Elsevier/Mosby, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

W, Jenne J., and Murphy Shirley 1944-, eds. Drug therapy for asthma: Research and clinical practice. New York: Dekker, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Friedrich, Kummer, ed. Asthma: Structural body-Theophylline today = strukturelle Grundlagen--Theophyllin heute. New York: Springer-Verlag, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dietz, D. NTP technical report on the toxicology and carcinogenesis studies of l-Epinephrine hydrochloride (CAS No. 55-31-2) in F344/N rats and B6C3F1 mice (inhalation studies). Research Triangle Park, NC: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jubber, Akeel Shamkhi. Assessment of measures of airway responsiveness and their use in the evaluation of bronchodilator drugs. Manchester: University of Manchester, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nageeb A.G.M Hassan. Evaluation of airway pharmacodynamic and pharmacokinetic properties of bronchoconstrictor and bronchodilator drugs in normal human subjects. Manchester: University of Manchester, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bills, Georgine W. Principles of pharmacology for respiratory care. 2nd ed. Albany: Delmar Publishers, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

C, Soderberg Robert, ed. Principles of pharmacology for respiratory care. Albany, N.Y: Delmar Publishers, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zug, Naser Abd-Asalam. Studies of the bronchodilator action of the long acting [beta]2-agonist (salmeterol) in normal human subjects. Manchester: University of Manchester, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Bronchodilator"

1

Calverley, P. M. A. "Symptomatic Bronchodilator Treatment." In Chronic Obstructive Pulmonary Disease, 419–45. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4899-4525-9_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Spina, D. "New Bronchodilator Drugs." In Handbook of Experimental Pharmacology, 153–78. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-662-09264-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Spahn, Joseph D., and Ryan Israelsen. "Bronchodilator Therapy for Asthma." In Allergy and Asthma, 1–31. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-58726-4_38-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Spahn, Joseph D., and Ryan Israelsen. "Bronchodilator Therapy for Asthma." In Allergy and Asthma, 841–71. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-05147-1_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Navelesi, P., P. Ceriana, and M. Delmastro. "Bronchodilator Therapy in Mechanically Ventilated Patients." In Yearbook of Intensive Care and Emergency Medicine 2002, 287–93. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-642-56011-8_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Navelesi, P., P. Ceriana, and M. Delmastro. "Bronchodilator Therapy in Mechanically Ventilated Patients." In Intensive Care Medicine, 287–93. New York, NY: Springer New York, 2002. http://dx.doi.org/10.1007/978-1-4757-5551-0_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pelosi, P., M. Croci, and A. Pesenti. "Airway Resistance and Bronchodilator Responsiveness in ARDS." In Yearbook of Intensive Care and Emergency Medicine, 487–98. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-80053-5_40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mehta, Sanjay, and Jeffrey M. Drazen. "Bronchodilator Actions of Nitric Oxide and Related Compounds." In Nitric Oxide in Pulmonary Processes: Role in Physiology and Pathophysiology of Lung Disease, 127–49. Basel: Birkhäuser Basel, 2000. http://dx.doi.org/10.1007/978-3-0348-8474-7_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Waldeck, B., O. A. T. Olsson, and L. Å. Svensson. "New Possibilities for the β-Adrenoceptor Agonist Bronchodilator Drugs." In Directions for New Anti-Asthma Drugs, 55–68. Basel: Birkhäuser Basel, 1988. http://dx.doi.org/10.1007/978-3-0348-9156-1_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Youlten, L. J. F., A. J. Williams, J. W. Ross, and D. H. Richards. "Studies in Healthy Volunteers can Demonstrate Bronchodilator Activity of Orally Administered Drugs." In Directions for New Anti-Asthma Drugs, 285–89. Basel: Birkhäuser Basel, 1988. http://dx.doi.org/10.1007/978-3-0348-9156-1_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bronchodilator"

1

Mathur, M., A. M. Al-Jumaily, G. Ijpma, and R. Alany. "Effects of Bronchodilators Combined With Oscillations on the Contracted Airway Smooth Muscle." In ASME 2010 International Mechanical Engineering Congress and Exposition. ASMEDC, 2010. http://dx.doi.org/10.1115/imece2010-38357.

Full text
Abstract:
Current asthma treatments using anti-inflammatory agents and airway smooth muscle (ASM) relaxants are expensive, variable in effectiveness and are associated with several cardiovascular side effects. Previous in vitro experiments conducted on ASM tissues suggest that oscillations applied to contracted muscle result in a reduction in the contractile ability of the tissue. This study focuses on investigating the combined effects of muscle relaxants (bronchodilators) and length oscillations on the dynamics of contracted ASM. Isolated porcine tracheal smooth muscle tissues are contracted using Acetylcholine. Isoproterenol (Iso), a β-agonist, is used as a bronchodilator to relax the contracted ASM. Our results suggest that the combined effect of Iso and breathing oscillations is noted to be greater than the added effects of Iso and breathing alone. It can be proposed that breathing oscillations aid the relaxation of ASM by Isoproterenol.
APA, Harvard, Vancouver, ISO, and other styles
2

Marcon, Alessandro, Josep M. Anto, Isa Cerveri, Thorarinn Gislason, Joachim Heinrich, Christer Janson, Deborah Jarvis, et al. "Can we use pre-bronchodilator spirometry to define post-bronchodilator airflow obstruction?" In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa5065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hegewald, Matthew, and Robert Jensen. "Bronchodilator response in healthy subjects." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.3207.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lazova, Snezhina, Guergana Petrova, Dimitrinka Miteva, Vera Papochieva, and Penka Perenovska. "Bronchodilator responsiveness after ICS treatment." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1245.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hangaard, Stine, Thomas Kronborg, Mads Nibe Stausholm, Simon Lebech Cichosz, and Ole Hejlesen. "Using the pre-bronchodilator spirometry curvature to improve estimation of post-bronchodilator airflow obstruction." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2644.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shishimorov, Ivan, Olga Magnitskaya, Oxana Fadina, Eleonora Belan, and Natalia Maliuzhinskaia. "Pharmacodynamic effects of nebulised bronchodilator combinations." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Desai, PK, S. Kapoor, N. Dy, and UB Nanavaty. "Aging and Bronchodilator Responsiveness in COPD Population." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4537.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Barros, Raquel, Cláudia Mourato, Khrystyna Budzak, Patrícia Araújo, Ana Sofia Oliveira, João Valença, and Cristina Bárbara. "Bronchodilator reversibility - differences between asthma and COPD." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa1119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pittman, Jessica E., Robin C. Johnson, and Stephanie D. Davis. "Bronchodilator Responsiveness By Infant Pulmonary Function Testing." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3916.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shin, H. J., T. O. Kim, and Y. S. Kwon. "Mono-Bronchodilator Therapy versus Dual Bronchodilator Therapy in Symptomatic COPD Patients: The Korea COPD Subgroup Study Team Cohort." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2790.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Bronchodilator' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography